News

Boston Scientific (BSX) stock declined 47% over the last 12 months to trade near $57. Despite total revenues growing 17.4% to $20.6 billion and net income margins improving to 17.3%, the P/E multiple contracted by 70%. The selloff was triggered by a Q4 2025 GAAP EPS miss and a significant full-year 2026 organic growth guidance cut. The company's management lowered the target from a 10 to 11% range down to 6.5 to 8.0%, attributing the reset to greater-than-expected market share loss in the Electr

When it comes to reliable dividend payouts, these three companies keep rewarding their long-term shareholders.

J&J's expanding pipeline, new drug approvals and rising sales from cancer medicines are expected to fuel growth.

Johnson & Johnson (NYSE:JNJ) closed the most recent session at $230.42, up 2.58% on the week as buyers rotated back into defensive healthcare names. Our 24/7 Wall St. price target for Johnson & Johnson is $252.01 over the next 12 months, implying 9.37% upside. The recommendation is buy, and our confidence level is 90%, the ... This Will Be Johnson and Johnson’s Stock Price in 2027

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

It has plenty of other qualities investors should take note of.

Johnson & Johnson (NYSE:JNJ) has launched the next generation Shockwave C2 Aero Coronary IVL Catheter for calcified coronary artery disease. The device is designed to improve flexibility, lesion crossing, and repositioning in complex coronary cases. The launch is positioned as a global rollout, targeting physicians treating patients with hardened coronary lesions. For investors watching NYSE:JNJ, this product introduction sits alongside a share price of $228.92 and multi year returns of...

(Updates with Novo Nordisk's response in the fourth and fifth paragraphs.) The US Supreme Court o

Johnson & Johnson (NYSE:JNJ) is included among the 10 Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026. On May 13, Leerink Partners upgraded Johnson & Johnson (NYSE:JNJ) to Outperform from Market Perform and raised its price target to $265 from $252.The firm said the company’s “strong new drug momentum” is […]

The retiree was 66, single, living in Pennsylvania, and relying on a $1.1 million brokerage account to supplement her Social Security income. Her goal was straightforward: generate about $55,000 a year from the portfolio to cover the gap between her guaranteed income and the cost of remaining in her home. She followed the standard retirement playbook ... The Tax-Loss Harvest That Cost a 66-Year-Old Retiree $2,400 in Wash-Sale Penalties She Never Saw Coming

ABBV's neuroscience sales jump 26% in Q1, driven by Vraylar, migraine drugs and Botox as new therapies fuel growth.

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning tradi

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

MSFT rides on surging enterprise AI demand, with Azure growth and Copilot adoption accelerating despite rising capex and margin pressure.

If you are wondering whether Johnson & Johnson at around US$226.71 is still a strong long term holding or starting to look stretched, the answer starts with understanding what you are really paying for today. The stock is up 2.4% over the past week, down 3.2% over the past month, and sits on a 9.3% year to date return, with a 54.0% one year return, 56.0% over three years, and 52.7% over five years. This gives you a wide range of recent price behaviour to put under the microscope. Recent...

Johnson & Johnson (NYSE:JNJ) presented early clinical data on JNJ-1900 (NBTXR3) for inoperable non-small cell lung cancer at the 2026 ESTRO Annual Meeting. The company shared positive Phase 2 feasibility and safety results for this nanoradioenhancer candidate in a high unmet medical need setting. The update highlights progress in Johnson & Johnson's late-stage oncology portfolio and adds a new element to its cancer care pipeline. Johnson & Johnson, known for its diversified healthcare...

The traditional 60/40 portfolio, 60% stocks and 40% bonds, has been the default retirement allocation for decades. Charles Schwab’s Modern Wealth Survey 2025 found that 42% of Americans believe that mix is outdated, and the skepticism is sharper among younger investors. 46% of Gen Z and 46% of Millennials agree the model no longer works, ... Bonds Now Make Up Just 8% of the Average Portfolio. What Replaced Them

Kiplinger’s Personal Finance May 2026 letter makes it clear that if you are looking for yield, the door is wide open across the entire risk spectrum. We are seeing a massive spread, with opportunities ranging from stable 3% municipal bonds to 13% for those willing to get aggressive with business development companies. This is unfolding ... Kiplinger’s May 2026 Letter Says Yields From 3% to 13% Are Available Right Now Despite Iran War Uncertainty

Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products and the launch of its GenesisX robotic system. Chairman and CEO David Fischel told investors that t

On episode 168 of the Rich Habits Podcast, co-host Robert Croak made a pitch that sounds almost too easy to be a strategy. He noted, “The easiest stream of income you can build because you’re already probably sitting on the cash. You just need to park it in the right vehicles.” His co-host, Austin, then ... Why Keeping Emergency Cash in Checking Costs You $15,000 Over a Decade

The retirement plan looked straightforward until March 2026. A 64-year-old couple in Pennsylvania had built a $2.4 million portfolio around a familiar target: roughly $96,000 a year in retirement spending supported by the classic 4% withdrawal framework. Then a new possibility entered the picture. The husband’s 88-year-old father, recently widowed and living alone in Florida, ... What Retirement Really Looks Like at 64 With $2.4 Million and a Father Moving Into the Guest Room Next Year

After 22 years, a couple sold their restaurant and suddenly found themselves staring at a very different balance sheet. The sale dropped $1.1 million in cash onto the table, adding to the $480,000 already sitting in a SEP-IRA. On paper, that looks like roughly $1.58 million in investable assets before taxes enter the chat like ... If You Have $480,000 Saved at 67 and Just Sold a Restaurant for $1.1 Million Cash, Here Is the Income Plan That Actually Holds

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.

The intrinsic value estimate for Johnson & Johnson has shifted slightly, with the fair value moving from US$252.42 to US$252.96 per share, a change of about 0.2%. That subtle move lines up with recent analyst research that focuses on execution around drugs like Icotyde, Inlexzo, Tecvayli and Tremfya, as well as on how the pipeline and broader healthcare positioning are shaping sentiment. As you read on, you will see how these price target tweaks fit into the wider story and what to watch as...

CoreWeave, Inc. (NASDAQ:CRWV) was among the stocks on Jim Cramer’s radar as he highlighted the importance of lower interest rates in sustaining the broader market rally. Answering a caller’s query about the stock during the episode, Cramer said: Okay, now, I gotta tell you… CoreWeave is what I call a stock that’s not for the […]

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson's CAPLYTA (lumateperone) showed superior efficacy and favorable safety in major depressive disorder in a new network meta-analysis. The study compared CAPLYTA to other FDA approved antipsychotics used as adjunctive treatment for major depressive disorder. Results were presented at a major neuroscience meeting, highlighting comparative effectiveness and tolerability versus competing therapies. For investors tracking NYSE:JNJ, this update on CAPLYTA arrives with the stock at...

I’ve been studying portfolio concentration for years, and one stat from Schwab’s On Investing podcast keeps echoing in my head. In 2022, the Magnificent Seven fell roughly 40% while the S&P 500 dropped 18%. Our data confirms the pain: SPY shed 20% that calendar year, while Meta Platforms (NASDAQ:META) collapsed 64%, NVIDIA (NASDAQ:NVDA) fell 51%, ... The Magnificent Seven Fell 40% While the S&P Dropped 18%: Here’s How Much Tech Concentration You Can Actually Afford

Isomorphic previously raised $600 million in external funding last year, which was also led by NYC’s Thrive Capital.